GlassScriptPhysician profile
Eric T Kirby
NPI 1811316565
$5,299.65
in general payments reported to CMS, 2019-2025
27 companies · $896 in 2025
The $896 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $766 · 2020: $16.61 · 2021: $432 · 2022: $946 · 2023: $821 · 2024: $1,422 · 2025: $896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,989 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,988.89 |
| Education | $149.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $923.43 | 2019-2025 | Monjuvi, Jakafi, Pemazyre |
| Emd Serono, INC. | $510.52 | 2022-2024 | Bavencio |
| Astrazeneca Pharmaceuticals LP | $406.02 | 2022-2025 | Calquence, Tagrisso |
| Seagen INC. | $366.25 | 2021-2023 | Tukysa |
| Pfizer INC. | $306.91 | 2022-2025 | |
| Genzyme Corporation | $276.60 | 2019-2025 | |
| Janssen Biotech, INC. | $257.05 | 2020-2025 | Carvykti, Rybrevant, Imbruvica |
| Celgene Corporation | $250.74 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $240.63 | 2019 | |
| Pharmacosmos Therapeutics INC. | $208.17 | 2022-2024 | Monoferric |
| Beone Medicines USA, INC. | $204.12 | 2025 | Brukinsa |
| E.R. Squibb & Sons, L.L.C. | $191.49 | 2019-2024 | Eliquis |
| Rigel Pharmaceuticals, INC. | $161.69 | 2022-2023 | Rezlidhia, Tavalisse |
| Regeneron Healthcare Solutions, INC. | $124.55 | 2024 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $118.30 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $115.58 | 2021 | |
| Abbvie INC. | $97.47 | 2024 | |
| Amgen INC. | $95.70 | 2019-2022 | |
| Beigene USA, INC. | $91.31 | 2024 | Brukinsa |
| Kite Pharma, INC. | $87.99 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $80.38 | 2019-2023 | Imbruvica |
| Agios Pharmaceuticals, INC. | $66.67 | 2019 | |
| Adc Therapeutics America, INC. | $43.72 | 2021-2023 | |
| Tempus Ai, INC | $28.37 | 2024 | |
| Geron Corporation | $16.99 | 2025 | Rytelo |
| Daiichi Sankyo INC. | $15.24 | 2019 | |
| Clovis Oncology, INC. | $13.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Kirby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.